City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  423  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17385

Principal Investigator: Maria Hahn, PhD
Sponsor: Institutional

Title:  Development of an Epigenetic Biomarker Panel for DCIS Invasiveness

COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17336 ClinicalTrials.gov Number: NCT03318562

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple-Negative Breast Cancer and Hepatocellular Carcinoma

COH Protocol Number: 17332 ClinicalTrials.gov Number: NCT03355066

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17313 ClinicalTrials.gov Number: NCT02642965

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

COH Protocol Number: 17311 ClinicalTrials.gov Number: NCT03057626

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

COH Protocol Number: 17305

Principal Investigator: Niki Tank, MD
Sponsor: Institutional

Title:  A Pilot Study to Profile the Gut Microbiome of Breast Cancer Patients that Develop Neuropathic Pain after Paclitaxel Treatment

COH Protocol Number: 17303

Principal Investigator: Anne Reb, RN, PhD
Sponsor: Institutional

Title:  GYN Oncology Survivorship Care: A Descriptive Pilot Study

COH Protocol Number: 17293 ClinicalTrials.gov Number: NCT03035253

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Navicixizumab (OMP-305B83) Plus FOLFIRI as Second Line Therapy in Subjects with Metastatic Colorectal Cancer

COH Protocol Number: 17290 ClinicalTrials.gov Number: NCT03298516

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

COH Protocol Number: 17277 ClinicalTrials.gov Number: NCT03267524

Principal Investigator: Virginia Sun, RN, PhD
Sponsor: Institutional

Title:  Walking for Recovery From Surgery: Pilot Study of a Prehabilitation Intervention for Older Adults with Cancer and their Family Caregivers

COH Protocol Number: 17273 ClinicalTrials.gov Number: NCT03331198

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

COH Protocol Number: 17270 ClinicalTrials.gov Number: NCT03157128

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

COH Protocol Number: 17265 ClinicalTrials.gov Number: NCT02981628

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

COH Protocol Number: 17240

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Single Patient IND for RB for the Use of AG-221 in the Treatment of AML

COH Protocol Number: 17235

Principal Investigator: Jessica Clague dehart, PhD
Sponsor: Institutional

Title:  The Effect of the "Living Well After Cancer" Program on Quality of Life and Metabolic Measures

COH Protocol Number: 17231

Principal Investigator: Dan Raz, MD
Sponsor: Institutional

Title:  Deciphering Gut and Tumor Microbiome Modulation of Response to Immune Checkpoint Blockage Therapy in Patients with Non-Small Cell Lung Cancer

COH Protocol Number: 17228 ClinicalTrials.gov Number: NCT02675452

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 17227 ClinicalTrials.gov Number: NCT03224819

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 17226 ClinicalTrials.gov Number: NCT03245424

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation

COH Protocol Number: 17219 ClinicalTrials.gov Number: NCT03112603

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)

COH Protocol Number: 17211

Principal Investigator: Behrouz Salehian, MD
Sponsor: Industrial

Title:  MEASuRE: Metreleptin Effectiveness and Safety Registry

COH Protocol Number: 17210 ClinicalTrials.gov Number: NCT02964013

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

COH Protocol Number: 17209 ClinicalTrials.gov Number: NCT03275103

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17208

Principal Investigator: Christina Yeon, MD
Sponsor: Institutional

Title:  Single Subject Protocol for BL– Treatment Use of Neratinib for ER Positive, PR Negative, HER-2 Positive Breast Cancer

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.